Burosumab
CAS 1610833-03-8Biologic
Overview
Burosumab is a recombinant human monoclonal antibody used for the treatment of X-linked hypophosphatemia (XLH), a rare genetic disorder. It works by binding to and inhibiting fibroblast growth factor 23 (FGF23), thereby increasing phosphate levels and improving bone health.
Therapeutic areas
Bone DiseasesGenetic DisordersPediatric Endocrinology
Verified Supplier Partner
Do you supply Burosumab? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.